Your browser doesn't support javascript.
loading
Palliative procedures for malignant gastric outlet obstruction: a network meta-analysis.
Tran, Khoi Van; Vo, Nguyen-Phong; Nguyen, Hung Song; Vo, Nhi Thi; Thai, Thi Bao Trang; Pham, Vu Anh; Loh, El-Wui; Tam, Ka-Wai.
Afiliação
  • Tran KV; Department of Surgery, Hue University of Medicine and Pharmacy, Hue University, Hue City, Viet Nam.
  • Vo NP; International PhD Program in Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan.
  • Nguyen HS; Department of Hepatobiliary and Pancreatic Surgery, Cho Ray Hospital, Ho Chi Minh City, Viet Nam.
  • Vo NT; Department of Pediatrics, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam.
  • Thai TBT; Intensive Care Unit Department, Children's Hospital 1, Ho Chi Minh City, Viet Nam.
  • Pham VA; Faculty of Nursing, Hue University of Medicine and Pharmacy, Hue University, Hue City, Viet Nam.
  • Loh EW; International PhD Program in Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan.
  • Tam KW; Department of Surgery, Hue University of Medicine and Pharmacy, Hue University, Hue City, Viet Nam.
Endoscopy ; 2024 May 31.
Article em En | MEDLINE | ID: mdl-38641337
ABSTRACT

BACKGROUND:

The optimal treatment for malignant gastric outlet obstruction (GOO) remains uncertain. This systematic review aimed to comprehensively investigate the efficacy and safety of four palliative treatments for malignant GOO gastrojejunostomy, endoscopic ultrasound-guided gastroenterostomy (EUS-GE), stomach-partitioning gastrojejunostomy (PGJ), and endoscopic stenting.

METHODS:

We searched PubMed, Embase, Cochrane Library, Scopus, and Web of Science databases, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform for randomized controlled trials (RCTs) and cohort studies comparing the four treatments for malignant GOO. We included studies that reported at least one of the following clinical

outcomes:

clinical success, 30-day mortality, reintervention rate, or length of hospital stay. Evidence from RCTs and non-RCTs was naïve combined to perform network meta-analysis through the frequentist approach using an inverse variance model. Treatments were ranked by P score.

RESULTS:

This network meta-analysis included 3617 patients from 4 RCTs, 4 prospective cohort studies, and 32 retrospective cohort studies. PGJ was the optimal approach in terms of clinical success and reintervention (P scores 0.95 and 0.90, respectively). EUS-GE had the highest probability of being the optimal treatment in terms of 30-day mortality and complications (P scores 0.82 and 0.99, respectively). Cluster ranking to combine the P scores for 30-day mortality and reintervention indicated the benefits of PGJ and EUS-GE (cophenetic correlation coefficient 0.94; PGJ and EUS-GE were in the same cluster).

CONCLUSION:

PGJ and EUS-GE are recommended for malignant GOO. PGJ could be the alternative choice in centers with limited resources or in patients who are unsuitable for EUS-GE.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article